First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2018.12.11
- Author:
Xiaoxiao PENG
1
;
Qing ZHOU
1
Author Information
1. Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangdong Lung Cancer Institute,
Guangzhou 510080, China.
- Publication Type:Journal Article
- Keywords:
First-line combination;
Immuno-oncology;
Lung neoplasms;
Programmed death-1/programmed death-ligand-1 inhibitors
- MeSH:
Animals;
Carcinoma, Non-Small-Cell Lung;
immunology;
therapy;
Humans;
Immunotherapy;
methods;
trends;
Lung Neoplasms;
immunology;
therapy
- From:
Chinese Journal of Lung Cancer
2018;21(12):924-930
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) inhibitor has become one of the important treatment options for patients with advanced non-small cell lung cancer (NSCLC). However, only a small subset of patients with NSCLC can currently receive single-agent PD-1 inhibitors as first-line therapy, for the limitations of population selection exclude most patients from immuno-oncology (IO) monotherapy. In order to expand the candidate population for IO first-line treatment and make more newly diagnosed patients benefit from IO treatment, a series of studies are focusing on the combination of IO and other drugs in NSCLC. We reviewed the latest clinical data of IO first-line combination therapy in recent years, suggesting that on the basis of PD-1/PD-L1 inhibitors, combined with other IO, chemotherapy, anti-angiogenic drugs, targeted therapy or radiotherapy may produce synergistic anti-tumor effects. It is expected to benefit more newly diagnosed patients.
.
